Blood Test Predicts Which Patients with Lung Cancer Will Benefit from Newly Approved Immunotherapy Drug
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.
